1. Scrip
  2. >>Therapy Areas
  3. >>Immunological

Early Beleodaq win for Spectrum bodes well for Onxeo

 
• By Donna Young

The FDA on 3 July surprised Spectrum Pharmaceuticals and its partner Topotarget – which is finalizing a merger with BioAlliance to form Onxeo – by granting approval of Beleodaq (belinostat) more than a month ahead of schedule as a treatment for patients with peripheral T-cell lymphoma (PTCL), a diverse group of rare and aggressive diseases, which account for up to 15% of all non-Hodgkin lymphomas.

The FDA on 3 July surprised Spectrum Pharmaceuticals and its partner Topotarget – which is finalizing a merger with BioAlliance to form Onxeo – by granting approval of Beleodaq (belinostat) more than a month ahead of schedule as a treatment for patients with peripheral T-cell lymphoma (PTCL), a diverse group of rare and aggressive diseases, which account for up to 15% of all non-Hodgkin lymphomas.

Shares of Henderson, Nevada-based Spectrum jumped 6.3%, or 55 cents, in morning trading on 3 July.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immunological

InflaRx Stock Sinks As Vilobelimab Fails Phase III Skin Trial

 
• By Kevin Grogan

A study of the German biotech's intravenous complement factor C5a antibody for pyoderma gangrenosum was stopped for futility.

GlycoEra’s Series B Cash Will Fund Efforts To Take On FcRn Inhibitor Class

 
• By Joseph Haas

GlycoEra unveiled a $130m series B financing, saying the proceeds would enable it to take its first clinical candidate through proof-of-concept in autoimmune diseases.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.

Merck & Co. CMO Barr On Breaking Into Immunology And Ophthalmology

 
• By Jessica Merrill

Chief medical officer Eliav Barr discussed Merck’s investment in new therapeutic areas and business development in an interview with Scrip.

More from Therapy Areas

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 
• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

 
• By Joseph Haas

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.

Merck & Co./Daiichi Pull Patritumab Deruxtecan BLA On Disappointing OS

 
• By Jessica Merrill

Patritumab deruxtecan is the lead antibody drug conjugate in a $22bn deal signed between the two partners, with the decision marking a disappointing setback